Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Liabilities and Shareholders Equity (2019 - 2023)

Alx Oncology Holdings' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $220.1 million for Q3 2023.

  • For Q3 2023, Liabilities and Shareholders Equity fell 30.72% year-over-year to $220.1 million; the TTM value through Dec 2023 reached $744.2 million, down 44.21%, while the annual FY2022 figure was $306.5 million, 19.38% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2023 was $220.1 million at Alx Oncology Holdings, down from $245.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $436.1 million in Q4 2020 and bottomed at $10.7 million in Q4 2019.
  • The 5-year median for Liabilities and Shareholders Equity is $317.7 million (2022), against an average of $301.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity soared 3984.43% in 2020 before it plummeted 30.72% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $10.7 million in 2019, then skyrocketed by 3984.43% to $436.1 million in 2020, then fell by 12.81% to $380.2 million in 2021, then dropped by 19.38% to $306.5 million in 2022, then fell by 28.18% to $220.1 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Liabilities and Shareholders Equity are $220.1 million (Q3 2023), $245.9 million (Q2 2023), and $278.1 million (Q1 2023).